$VNRX News

VolitionRx Publishes Paper On The Prognostic Value Of Its Nu.Q Cancer Assay In Newly Diagnosed Lung Cancer Patients

VolitionRx Announces Collaboration with Sysmex

VolitionRx Announces Pricing of $4.6 Million Public Offering

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

Full Transcript: VolitionRX Q1 2026 Earnings Call

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VNRX: Zacks SCR Refreshes its Latest Report With Volition's Financials, Prices, EPS Estimates, Market Statistics and Target Price Adjusted for 1-for-20 Reverse-Split

VNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1-for-20 reverse-split that will become effective on April 28th.

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American

VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American